Skip to content
  • Pipeline
    • Overview
      • Dovitinib
      • Stenoparib
      • Ixempra®
      • Additional Programs
    • Clinical Trials
  • Technology
    • The DRP® Method
    • Scientific Publications
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Investors
    • Overview
    • News
    • Stock Info
    • Financials
    • Governance
    • Resources
    • Presentations
  • Contact
    • General Inquires
  • Careers
    • Join Allarity
Menu
  • Pipeline
    • Overview
      • Dovitinib
      • Stenoparib
      • Ixempra®
      • Additional Programs
    • Clinical Trials
  • Technology
    • The DRP® Method
    • Scientific Publications
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Investors
    • Overview
    • News
    • Stock Info
    • Financials
    • Governance
    • Resources
    • Presentations
  • Contact
    • General Inquires
  • Careers
    • Join Allarity
Search
Close

Pipeline: Clinical Trials

Clinical trials involving Allarity assets include:

Dovitinib

Dovitinib

Stenoparib (2X-121​)

Stenoparib (2X-121) (Phase 2)

Under previous name (E7449)

Ixempra®

Ixempra®

LiPlaCis®

LiPlaCis (Phase 2)

2X-111

Under previous name (2B3-101)

Pipeline
Overview
– Dovitinib
– Stenoparib
– Ixempra®
– Additional Programs
– Clinical Trials

Technology The DRP® Platform Scientific Publications

About Us
Overview
Leadership
Board of Directors
SAB
Partnering

Investors
Overview
News 
Stock Info
Financials
Governance
Resources
Presentations

Newsroom
Top News
Media Contact

Contact
General Inquires

Careers
Join Allarity

Copyright © 2023 Allarity Therapeutics, Inc. All Rights Reserved.

Unless otherwise specified, all product and service name appearing in this internet site are trademark owned by or licensed to Allarity, its subsidiaries or affiliates. No use of any Allarity trademark, trade name, or trade dress in this site may be made without the prior written authorization of Allarity, except to identify the product or services of company.

Terms of Use 

Privacy Policy

Social Media Policy

Cookie Policy
Allarity Therapeutics Logo

United States:
24 School Street, 2nd Floor,
Boston, MA 02108
USA
Tel. +1 401-426-4664

Denmark:
Venlighedsvej 1
2970 Hoersholm
Denmark
Tel. +45 88 74 24 14
CVR: 34623562